AIM2 and neoplasm: Intravenous administration of AIM2-deficient dendritic cells (DCs) using a vaccination strategy results in the homing of the DCs to the tumor and enhanced efficacy of adoptive cell therapy (ACT) as well as anti-PD-1 immunotherapy, thereby achieving therapeutic responses in cold melanomas.